Castle Biosciences, Inc. (CSTL)
NasdaqGM
Price as at 30 Sept 2026, 17:20 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Castle Biosciences, Inc. trades at $35.35. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Castle Biosciences, Inc.
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
9 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$8.85M · 0.0% of book
- Steve Cohen, Point72 Asset Management, L.P.$8.52M · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$6.33M · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$4.90M · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$3.97M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in CSTL
Trades in CSTL disclosed by members of Congress and executive-branch officials, latest first:
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 23 Dec 2020 · disclosed 11 Jan 2021
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
Common questions
Which funds own CSTL?
9 of the institutions we track reported a position in CSTL in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its CSTL data?
Fundamentals for CSTL come from company filings and exchange data, as listed on NasdaqGM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 17:20 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for CSTL, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.